Vorinostat Patent Expiration
Vorinostat is Used for treating cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL). It was first introduced by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc
Vorinostat Patents
Given below is the list of patents protecting Vorinostat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zolinza | US8450372 | Formulations of suberoylanilide hydroxamic acid and methods for producing same | Mar 18, 2028 | Msd Sub Merck |
| Zolinza | US7456219 | Polymorphs of suberoylanilide hydroxamic acid | Mar 11, 2027 | Msd Sub Merck |
| Zolinza | US8093295 | Formulations of suberoylanilide hydroxamic acid and methods for producing the same | May 16, 2026 | Msd Sub Merck |
| Zolinza | US7399787 | Methods of treating cancer with HDAC inhibitors | Feb 09, 2025 | Msd Sub Merck |
| Zolinza | US7851509 | Polymorphs of suberoylanilide hydroxamic acid |
Feb 21, 2024
(Expired) | Msd Sub Merck |
| Zolinza | US7652069 | Polymorphs of suberoylanilide hydroxamic acid |
Mar 04, 2023
(Expired) | Msd Sub Merck |
| Zolinza | US7732490 | Methods of treating cancer |
Mar 04, 2023
(Expired) | Msd Sub Merck |
| Zolinza | US8067472 | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
Mar 04, 2023
(Expired) | Msd Sub Merck |
| Zolinza | US8101663 | Polymorphs of suberoylanilide hydroxamic acid |
Mar 04, 2023
(Expired) | Msd Sub Merck |
| Zolinza | USRE38506 | Potent inducers of terminal differentiation and methods of use thereof |
Nov 29, 2013
(Expired) | Msd Sub Merck |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vorinostat's patents.
Latest Legal Activities on Vorinostat's Patents
Given below is the list recent legal activities going on the following patents of Vorinostat.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 01 Jan, 2024 | US8067472 |
| Maintenance Fee Reminder Mailed Critical | 17 Jul, 2023 | US8067472 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Jun, 2023 | US8093295 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 May, 2022 | US7851509 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Nov, 2021 | US7732490 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Jun, 2021 | US7652069 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Sep, 2020 | US8450372 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Apr, 2020 | US7456219 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Dec, 2019 | US7399787 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Jun, 2019 | US8093295 |
Vorinostat's Family Patents
